S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Top Wellness Nasdaq Stock for 2023 (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Top Wellness Nasdaq Stock for 2023 (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Top Wellness Nasdaq Stock for 2023 (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Top Wellness Nasdaq Stock for 2023 (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023

Vincerx Pharma (VINC) Stock Forecast, Price & News

$1.01
-0.03 (-2.88%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.98
$1.09
50-Day Range
$0.66
$1.20
52-Week Range
$0.63
$1.95
Volume
176,966 shs
Average Volume
93,193 shs
Market Capitalization
$21.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Vincerx Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
296.0% Upside
$4.00 Price Target
Short Interest
Healthy
1.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$26,030 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.85) to ($0.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.89 out of 5 stars

Medical Sector

52nd out of 973 stocks

Pharmaceutical Preparations Industry

12th out of 449 stocks


VINC stock logo

About Vincerx Pharma (NASDAQ:VINC) Stock

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

VINC Price History

VINC Stock News Headlines

Advisor to FBI: Sell META now
Stocks just keep going up. But all isn’t what it seems, according to an FBI and Pentagon advisor. Find out what he knows, here.
Advisor to FBI: Sell META now
Stocks just keep going up. But all isn’t what it seems, according to an FBI and Pentagon advisor. Find out what he knows, here.
Vincerx Pharma Inc (VINC) Gets a Buy from SVB Securities
VINC Vincerx Pharma, Inc.
See More Headlines
Receive VINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter.

VINC Company Calendar

Last Earnings
8/07/2023
Today
9/29/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VINC
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+296.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-65,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.25 per share

Miscellaneous

Free Float
16,977,000
Market Cap
$21.59 million
Optionable
Not Optionable
Beta
0.41
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Ahmed M. Hamdy M.D. (Age 58)
    Founder, Chairman & CEO
    Comp: $609.84k
  • Dr. Raquel E. Izumi Ph.D. (Age 53)
    Founder, Pres, COO, Sec. & Director
    Comp: $551.66k
  • Mr. Alexander A. Seelenberger M.B.A.Mr. Alexander A. Seelenberger M.B.A. (Age 44)
    MBA, Chief Financial Officer
    Comp: $458.03k
  • Mr. Tom C. Thomas J.D.Mr. Tom C. Thomas J.D. (Age 64)
    Founder, Gen. Counsel & Chief Legal Officer
  • Dr. John C. Byrd M.D.
    Founder & Chairman of Scientific Advisory Board
  • Dr. Hans-Georg Lerchen Ph.D.
    Chief Scientific Officer
  • Ms. Gabriela Jairala
    Sr Exec. Director of Investor Relations & Corp. Communications
  • Ms. Karen Quarford
    VP of Quality Operations & Compliance
  • Ms. Melissa Merrick SPHR
    Sr. Director of People & Culture and Head of Human Resource
  • Dr. Beatrix Stelte-Ludwig Ph.D.
    Exec. Chief Devel. Officer













VINC Stock - Frequently Asked Questions

Should I buy or sell Vincerx Pharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VINC shares.
View VINC analyst ratings
or view top-rated stocks.

What is Vincerx Pharma's stock price forecast for 2023?

2 Wall Street analysts have issued 12-month price objectives for Vincerx Pharma's stock. Their VINC share price forecasts range from $3.00 to $5.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 296.0% from the stock's current price.
View analysts price targets for VINC
or view top-rated stocks among Wall Street analysts.

How have VINC shares performed in 2023?

Vincerx Pharma's stock was trading at $1.02 at the start of the year. Since then, VINC stock has decreased by 1.0% and is now trading at $1.01.
View the best growth stocks for 2023 here
.

When is Vincerx Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our VINC earnings forecast
.

How were Vincerx Pharma's earnings last quarter?

Vincerx Pharma, Inc. (NASDAQ:VINC) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.13.

What is Vincerx Pharma's stock symbol?

Vincerx Pharma trades on the NASDAQ under the ticker symbol "VINC."

How do I buy shares of Vincerx Pharma?

Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vincerx Pharma's stock price today?

One share of VINC stock can currently be purchased for approximately $1.01.

How much money does Vincerx Pharma make?

Vincerx Pharma (NASDAQ:VINC) has a market capitalization of $21.59 million. The company earns $-65,370,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.

How can I contact Vincerx Pharma?

Vincerx Pharma's mailing address is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. The official website for the company is vincerapharma.com. The company can be reached via phone at 650-800-6676.

This page (NASDAQ:VINC) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -